Edward Winslow Swanson Net Worth

The estimated Net Worth of Edward Winslow Swanson is at least $960 dollars as of 11 June 2019. Edward Swanson owns over 2,000 units of PolarityTE Inc stock worth over $960 and over the last 7 years Edward sold PTE stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Edward Swanson PTE stock SEC Form 4 insiders trading

Edward has made over 5 trades of the PolarityTE Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Edward bought 2,000 units of PTE stock worth $11,320 on 11 June 2019.

The largest trade Edward's ever made was buying 2,000 units of PolarityTE Inc stock on 11 June 2019 worth over $11,320. On average, Edward trades about 757 units every 91 days since 2017. As of 11 June 2019 Edward still owns at least 4,000 units of PolarityTE Inc stock.

You can see the complete history of Edward Swanson stock trades at the bottom of the page.

What's Edward Swanson's mailing address?

Edward's mailing address filed with the SEC is 615 Arapeen Dr #102, Salt Lake City, UT 84108, USA.

Insiders trading at PolarityTE Inc

Over the last 6 years, insiders at PolarityTE Inc have traded over $998,958 worth of PolarityTE Inc stock and bought 381,180 units worth $1,230,731 . The most active insiders traders include Steve Gorlin, Peter A Cohen et Paul Elliot Mann. On average, PolarityTE Inc executives and independent directors trade stock every 21 days with the average trade being worth of $3,753. The most recent stock trade was executed by Chris Nolet on 12 January 2023, trading 36,497 units of PTE stock currently worth $8,759.

What does PolarityTE Inc do?

polarityte, inc. (nasdaq: cool) is the owner of a novel regenerative medicine and tissue engineering platform developed and patented by denver lough md, phd. this radical and proprietary technology employs a patients'​ own cells for the healing of full-thickness functionally-polarized tissues. if clinically successful, the polarityte platform will be able to provide medical professionals with a truly new paradigm in wound healing and reconstructive surgery by utilizing a patient's own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. it is because polarityte uses a natural and biologically sound platform technology, which is readily adaptable to a wide spectrum of organ and tissue systems, that the company and its world-renowned clinical advisory board, are poised to drastically change the field and future of translational regenerative medicine. more info can be found online at www.polarityte.com welcome to the shift™

Complete history of Edward Swanson stock trades at PolarityTE Inc

PolarityTE Inc executives and stock owners

PolarityTE Inc executives and other stock owners filed with the SEC include:

• Richard Hague,
  Pres & CEO
• Cameron J. Hoyler,
  Gen. Counsel, Sec. and Exec. VP of Corp. Devel. & Strategy
• Daniel Gasiorowski,
  Investor Relations Contact Officer
• Wladyslaw Zmuda,
  Member of the Supervisory Board
• Michal Zadlo,
  Member of the Supervisory Board
• Beata Sobocinska,
  Member of the Supervisory Board
• Kamila Krawiec,
  Member of the Supervisory Board
• Michal Herominski,
  Member of the Supervisory Board
• Patryk Gall,
  Member of the Supervisory Board
• Emil Cybulski,
  Member of the Supervisory Board
• Pawel Cieslik,
  Member of the Supervisory Board
• Maria Biernacik-Bankowska,
  Member of the Supervisory Board
• Agnieszka Kosno,
  Chief Accounting Officer
• Zbigniew Stawinoga,
  Chairman of the Management Board
• Rafal Markiewicz,
  Chairman of the Supervisory Board
• Mark E. Lehman J.D.,
  Chief Legal Officer
• Ryan Mathis M.D.,
  Chief Medical Officer
• Dr. Jon Anthony Joseph Burrows B.Sc., M.Sc., Ph.D.,
  Sr. VP of Corp. Devel. & Pres of Contract Services
• Dr. Stephen Milner M.D., DDS, DSc, FRCSE, FACS,
  Chief Clinical Officer & Member of Clinical Advisory Board
• Alain Adam,
  VP of Sales
• Angela Ziegler,
  VP of Marketing & PR
• Rich Haerle,
  VP of Investor Relations & Strategy
• Nikolai Sopko,
  Chief Scientific Officer and VP of R&D
• Jacob Alexander Patterson,
  Chief Financial Officer
• Jacob Alexander Patterson,
  Chief Financial Officer
• Chris Nolet,
  Director
• Jessica Xiaolin Shen,
  Director
• David B Seaburg,
  Director
• Jon Mogford,
  Director
• Rainer M Erdtmann,
  Director
• Peter A Cohen,
  Director
• Paul Elliot Mann,
  Chief Financial Officer
• Edward Winslow Swanson,
  Chief Trans. Med. Officer
• Steve Gorlin,
  Director
• Jeffrey Hansen Dyer,
  Director
• Willie C. Bogan,
  Director
• Minnie Baylor Henry,
  Director
• Denver Lough,
  
• Richard Hague,
  Chf. Exec. Off. & Pres.
• Cameron J. Hoyler,
  Gen. Counsel & Exec. VP